New insider activity at Rocket Pharmaceuticals ( (RCKT) ) has taken place on February 28, 2025.
Jonathan David Schwartz, the Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, recently sold 15,093 shares of the company’s stock. This transaction amounted to a total value of $223,965.
Recent Updates on RCKT stock
Rocket Pharmaceuticals has recently made significant strides in its gene therapy pipeline, highlighted by the publication of the Phase 1 study of RP-A501 for Danon disease and long-term data showing its safety and efficacy. The company is progressing with the Phase 2 pivotal trial of RP-A501 and the Phase 1 trial of RP-A601 for PKP2-ACM, with plans to submit the IND for BAG3-DCM in 2025. Despite these advancements, JPMorgan slightly lowered its price target for Rocket Pharmaceuticals, reflecting cautious optimism as the company continues to develop its programs. The company’s financial position remains strong, with sufficient resources to fund operations into the third quarter of 2026, supporting ongoing development and manufacturing efforts.
More about Rocket Pharmaceuticals
YTD Price Performance: -25.16%
Average Trading Volume: 1,477,512
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.01B
Questions or Comments about the article? Write to editor@tipranks.com